Treatment of ANCA-associated systemic vasculitis

Bulletin of the NYU Hospital for Joint Diseases

Volumn 64, Issue 1-2, 2006, Pages 60-66

  Belmont, H Michael ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; SULFONAMIDE;

ANCA ASSOCIATED VASCULITIS; ANTIBIOTIC THERAPY; BLADDER CARCINOMA; BLADDER DISEASE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CYTOPENIA; DRUG HYPERSENSITIVITY; FIBROSIS; GLOMERULONEPHRITIS; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOPATHOGENESIS; INFECTION; KIDNEY FAILURE; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; SIDE EFFECT; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; REMISSION INDUCTION; TREATMENT OUTCOME; VASCULITIS;

EID: 33750294133     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Falk RJ, Jennette JC. Thoughts about the classification of small vessel vasculitis. J Nephrol. 2004;17(suppl 8):S3-S9.
2. Samarkos M, Loizou S. The clinical spectrum of primary renal vasculitis. Semin Arthritis Rheum. 2005;35:95-111.
3. Langford CA. Update on Wegener's granulomatosis. Cleve Clin J Med. 2005;72:689-90, 693-7.
4. Hogan S, Falk R, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143:621-31.
5. Sinico RA, Di Toma L. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2589-93.
6. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143:632-8.
7. Collins CE, Quismorio FP Jr. Pulmonary involvement in microscopic polyangiitis. Curr Opin Pulm Med. 2005;11:447-51.
8. Agard C, Mouthon L, Mahr A, Guillevin L. Microscopic polyangiitis and polyarteritis nodosa: how and when to start? Arthritis Rheum. 2003;49:709-15.
9. Merkel PA, Seo P. Vasculitis Clinical Research Consortium. OMERACT 7. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. J Rheumatol. 2005;32:2488-95.
10. Pagnoux C, Mahr A, Cohen P. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine. 2005;84:115-28.
11. Bougarit A, Le Toumelin P. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 95 patients. Medicine. 2005;84:323-30.
12. Canseaud Y, Tamby MC. Analysis of autoantibody repertoires in small- and medium-sized vessels and vasculitides. Evidence for specific perturbations in polyarteritis nodosa, microscopic polyangiitis, Churg-Strauss syndrome and Wegener's granulomatosis. J Autoimmun. 2005;24:169-79.
13. Jennette JC, Ewert BH, Falk RJ. Do antineutrophil cytoplasmic autoantibodies cause Wegener's granulomatosis and other forms of necrotizing vasculitis? Rheum Dis Clin North Am. 1993;19:1-14.
14. Ambrose L, Little M, Nourshargh S, Pusey CD. Anti-proteinase 3 antibody binding to neutrophils as demonstrated by confocal microscopy. Kidney Int. 2005;68:2912-3.
15. Van Rossum AP, Vandergeld YM, Limburg PC, Kallenberg CG. Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils. Kidney Int. 2005;68:537-41.
16. Huugen D, Tervaert JW, Heeringa P. Antineutrophil cytoplasmic autoantibodies and pathophysiology: new insights from animal models. Curr Opin Rheumatol. 2004;16:4-8.
17. Abdel-Salam B, Iking-Konert C, Schneider M, Andrassy K, Hansch GM. Autoantibodies to neutrophil cytoplasmic antigens (ANCA) do not bind to polymorphonuclear neutrophils in blood. Kidney Int. 2004;66:1009-17.
18. Hoffman GS. Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritis Rheum. 1997;40:2099-104.
19. De Groot K, Adu D, Savage CO, EUVAS (European Vasculitis Study Group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16:2018-27.
20. Adu D, Luqmani RA. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997;90:401-9.
21. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114:463-9.
22. Molloy ES, Langford CA. Advances in the treatment of small vessel vasculitis. Rheum Dis Clin North Am. 2006;32:157-72.
23. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351-61.
24. Jayne D, Rasmussen N, Andrassy K, et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44.
25. Langford CA, Talar-Williams C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. 2004;51:278-83.
26. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005;20:2725-32.
27. Weir A, Lipman M, Congleton J. Co-trimoxazole in Wegener's granulomatosis. N Engl J Med. 1996;5:335:1769-70.
28. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:262-8.
29. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol. 2005;34:229-32.
30. Bachemeyer C, Cadranel JF, Dementis R. Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis. Nephrol Dial Transplant. 2005;20:1274.
31. Ferraro AJ, Day CJ, Drayson MT, Savage CO. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005;20:622-5.
32. Sneller MC. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum. 2005;52:1-5.
33. Ericsson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med. 2005;257:540-8.